Which third-generation cephalosporin is partnered with Avycaz?

Ceftazidime is the correct choice as it is the third-generation cephalosporin that is partnered with Avycaz (ceftazidime/avibactam), which is a combination therapy used primarily for the treatment of complicated infections caused by certain multi-drug resistant Gram-negative bacteria.

The significance of this partnership lies in the innovative mechanism of action provided by avibactam, a beta-lactamase inhibitor that enhances the effectiveness of ceftazidime against beta-lactamase-producing pathogens. By inhibiting these enzymes, the combination allows for the continuation of ceftazidime's therapeutic effects, making it a valuable option in managing complicated urinary tract infections and intra-abdominal infections among others.

The other options, while being third-generation cephalosporins, do not have this partnership with Avycaz and are used in different clinical settings without the added benefit of a beta-lactamase inhibitor. This highlights the unique and crucial role of ceftazidime in conjunction with avibactam in contemporary antibiotic therapy for resistant infections.